Oral Malignant Burkitt’s Lymphoma and It’s Problems
DOI:
https://doi.org/10.18196/imunity.v1i1.28Keywords:
burkitt’s lymphoma, oral cancer, antitumorAbstract
A non-Hodgkin lymphoma with rapid growth and aggressive behavior is Burkitt's lymphoma. Burkitt's lymphoma (BL) is also an oral cancer of lymphoid origin with a high percentage of occurrences and includes an advanced B-cell neoplasm. Fundamentally, the exact cause of BL is unknown. This disease commonly occurs in people with weakened immune systems or children related to the Epstein-Barr virus (EBV) and chronic malaria. Burkitt lymphoma can be fatal. Burkitt lymphoma is a rare but highly aggressive (fast-growing) B-cell non-Hodgkin lymphoma (NHL). This disease may affect the jaw, central nervous system, bowel, kidneys, ovaries, or other organs Cancer cells in BL can spread to all parts of the body. Inhibiting the proliferation of BL oral cancer cells requires a viable and efficient plan. One of them is using medicinal plants whose antitumor potential needs to be scientifically tested. However, Burkitt lymphoma is often very responsive to the currently recommended intensive chemotherapy regimens, and cure rates for this disease remain high. Studies show people who receive treatment right away have high rates of remission, meaning after treatment they don’t have symptoms or signs of the condition. The aim of this review is to discuss Burkitt's lymphoma (BL) in diagnosis and treatment. Burkitt's lymphoma, or Raji cell, is a B-cell non-Hodgkin lymphoma that is very aggressive
References
WHO Report: Number of Worldwide Cancer Cases to Double by 2050 | Best Countries | U.S. News (usnews.com)
Regezi, J. A., Sciubba, J. J., & Jordan, R. C., Oral Pathology: Clinical Pathologic Correlations (4th ed.). Philadelphia: Elsevier.2003
LaCasce, C. J., How I treat Burkitt lymphoma in adults. Blood, 2014, November).,124, 2913-2921.
Hecht, J., & Aster, J. (2000, November). Molecular Biology of Burkitt's Lymphoma. Journal of Clinical Oncology, (2000, November) 18(21), 3707-3721.
Manerba, M., Ianni, L. D., Fiume, L., Roberti, M., Recanatini, M., & Stefano, G. D., Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin. European Journal of Pharmaceutical Sciences, 2015., 1-8.
Shirmanova, M. V., Druzhkova, I. N., Lukina, M. M., Dudenkova, V. V., Ignatova, N. I., Snopova, L. B., et al. Chemotherapy with cisplatin: Insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo. Scientific Reports, 2017., 1-13.
Robbins Robbins, S., Kumar, V., Abbas, A., & Aster, J., Basic Pathology (9th ed.). Canada: Elsevier Saunders. 2013.
Maramis, W., Catatan Ilmu Kedokteran Jiwa. Surabaya: Airlangga University Press., 2005
Wargasetia Wargasetia, T. L., Peran Gen p63 dalam Regulasi Proiferasi Sel., Jurnal Kedokteran Maranatha , 2008., VIII(2), 1-8.
Asmuddin. (2004, Juli). Peran Gen p16 pada Siklus Sel terhadap Pembentukan Kanker Jurnal Kedokteran Maranatha, (2004, Juli) IV(1), 63-74.
Lodish, H., Berk, A., Zipursky, S. L., Matsudaira, P., Baltimore, D., & Darnell, J Molecular Cell Biology (4th ed.). New York: WH Freeman and Co.2000.
Hartwell, L., & Kastan, M., Cell Cycle Control and Cancer. Science (266), 1994.,1821- 1828.
Wane Wanenoor, R., Proses Siklus Sel Pada Mamalia dan Peran P53 dalam Siklus Sel. Retrieved 2011., Agustus 23, 2018, from http://wanenoor.blogspot.com
Murray, R. K., A.Bender, D., M.Botham, K., J.Kennelly, P., W.Rodwell, V., & Weil, P. (2016). Struktur, Fungsi dan Replikasi Makromolekul Pembawa Informasi. In Harper's Illustrated Biochemistry (29th ed., p. 414). EGC Medical Publisher.
Dharmayanti, N. L., Kajian Biologi Molekuler: Gen Suppressor Tumor p53 sebagai Target Gen dalam Pengobatan Kanker. Wartazoa, 2003., 13(3), 99-107.
Naresh, M, R., L, A., N, H., V, C., E, R., et al , Lymphomas in sub-Saharan Africa--what can we learn and how can we help in improving diagnosis, managing patients and fostering translational research? British Journal of Haematology, (2011, September) 154(6), 1-17.
Parkin, D.M., Stiller, C.A., Draper, G.J. & Bieber, C.A. (1988) The international incidence of childhood cancer. International Journal of Cancer, 1988., 42, 511– 520
Cassidy, J., Bissett, D., & Obe, R. A.. Oxford Handbook, 2002.
Nafianti, S., Windiastuti, E., & Gatot, D.. Gambaran Limfoma Burkitt di Departemen Ilmu Kesehatan Anak RSUP Cipto Mangunkusumo Jakarta. Sari Pediatri, 2008, 10 (1), 47-52.
Guthrie, T., & Lopez, K, Basics of Cancer Treatment. A Cancer Education and Training Program for American Indians and Alaska Natives,2022, 85-87.
Fairchild, A., Tirumani, S. H., Rosenthal, M. H., Howard, S. A., Krajewski, K. M., Nishino, M., et al.. Hormone-dependent cancers are sensitive. American Rontgen Ray Society, (2015, June), 620-630.
Ferry, J. A. (2006). Burkitt’s Lymphoma: Clinicopathologic Features and Differential Diagnosis. The Oncologist, 2006., 11(4), 375-383.
Dave, K, F., GW, W., LT, L., P, K., EJ, B., et al., Molecular diagnosis of Burkitt's lymphoma. The New England Journal of Medicine, 2006., 354(23), 2431-2442.
Molyneux, E. M., Rochford, R., Griffin, B., Newton, R., Jackson, G., Menon, G., et al., Burkitt's lymphoma. The Lancet, 2012., 379(9822), 1234-1244.
Supriatno, Dyah Irnawati, Ana Medawati., Antisense oligonucleotide p45Skp-2 suppresses migratory chemotactic and metastasis of oral malignant Burkitt’s lymphoma cell through down-regulation of MTA-1 and induction of E-cadherin mechanism. Padjadjaran Journal of Dentistry. 2020;32(3):220-226.
Supriatno, Irnawati D, Medawati A, Entin Yuletnawati S. Downregulation of MTA-1, complex of CDK2–cyclin E, and NF-kB expressions as a molecular target therapy of oral Burkitt’s lymphoma cells mediated by sense KIP-1 and antisense SKP-2. J Int Oral Health, . 2021;13:493-8
Medawati, A, Supriatno, Mubarika, S., Widyarini, S., Ethyl Acetate Fraction of Papua’s Ant Nest Plant (Myrmecodia Pendens) Induces Cell Cycle Arrest and Apoptosis of an Oral Malignant Burkitt Lymphoma Cell through Down Regulation of Cyclin E–CDK2 Complex., Indian Journal of Public Health Research and Development, Vol.11/No.2, pp: 1034
